Quick Win By The Algorithm: FDA Springs SRPT To Life

Quick Win By The Algorithm

Sarepta Therapeutics, Inc. (SRPT)

On August 19, 2016 the I Know First algorithm gave a bullish signal for Sarepta Therapeutics, Inc. for 1 month. In accordance with the algorithm’s prediction, Sarepta Therapeutics, Inc. rose 92.37% since the article was published, resulting in a quick win by the algorithm.

Quick Win By The Algorithm

Sarepta Therapeutics, Inc. (SRPT) is a biopharmaceutical company focusing on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen.  The company was founded in 1890 and is headquartered in Cambridge, United Kingdom.


The biopharmaceutical industry is a volatile industry. A company’s financial future could be decided by the decisions made from the Food Drug Administration (FDA).  Sarepta Teheraoetics, Inc. has developed the Exonsdys 51.  This is the first drug to treat Duchenne muscular dystrophy, or DMD.  DMD is a genetic disorder in muscle weakness affecting 1 out of every 3,600 male. At first the company was met with skepticism after filing with the FDA seeking approval for the drug. However, the market was surprised to learn the FDA ultimately gave its approval for the drug.  In its accelerated approval program, the drug will be available for sale based upon its initial data.  As a result, the company’s stock increased dramatically, making it among the biggest gainers in September 19th.  The next day, RBC Capital Markets upgraded its rating of the stock to outperform and increased its price target from $5 to $83 a share.  As the I Know First algorithm predicted, Sarepta Therapeutics increased in value since the release of the article.

This bullish forecast on SRPT was sent to current I Know First subscribers on August 19th, 2016.